Engineering catalytically defective forms of HIV protease to modulate its activity.
Craik
C S
CS
Department of Pharmaceutical Chemistry, University of California at San Francisco 94143, USA.
Babé
L M
LM
Dauber
D
D
McPhee
F
F
Rosé
J
J
Unal
A
A
D000818:Animals; D019380:Anti-HIV Agents; D002384:Catalysis; D019281:Dimerization; D016333:HIV Protease / Q000235:genetics* / Q000378:metabolism*; D015497:HIV-1 / Q000201:enzymology* / Q000502:physiology; D006801:Humans; D015202:Protein Engineering; D014771:Virion
D019380:Anti-HIV Agents; D016333:HIV Protease